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Acute phase protein concentrations  
in dogs with nasal disease
D. Sheahan, R. Bell, R. J. Mellanby, A. G. Gow, E. Friend, J. Heller,  
L. M. Bence, P. D. Eckersall
The concentrations of C-reactive protein (CRP), serum amyloid A, haptoglobin (Hp) and 
α
1
-acid glycoprotein were measured in dogs with clinical signs of nasal disease and compared 
with those of healthy dogs in order to determine the expression of these proteins in cases of 
canine nasal disease. A significant difference (P<0.001) between the symptomatic group and 
the control group was found for both CRP and Hp. Among the animals with nasal disease, a 
significant intergroup difference (P<0.05) was found in the expression of Hp between dogs 
with aspergillosis and those with chronic rhinitis.
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Acute phAse proteins (Apps) are serum proteins whose concen-
trations change as part of an innate host defence mechanism called 
the acute phase response. the acute phase response to inflammation 
protects the host from disease and injury, minimises tissue damage 
and enhances the rate of repair (eckersall 2000). the acute phase 
response is stimulated by the release of proinflammatory cytokines 
including interleukin-1, tumour necrosis factor-α and interleukin-6 
from monocytes and macrophages in response to tissue damage or 
infection (Dinarello 1984, heinrich and others 1990). positive Apps, 
which include c-reactive protein (cRp), serum amyloid A (sAA), 
haptoglobin (hp), α1-acid glycoprotein (AGp) and caeruloplasmin, 
all show increased plasma concentrations after tissue injury, where-
as both albumin and transferrin decrease in concentration and are 
described as negative Apps. Both cRp and sAA are considered to be 
major Apps because their concentrations in plasma are characterised 
by an early sharp rise followed by a rapid decline. hp and AGp are 
moderate Apps: they show more gradual increases of smaller magni-
tude, and then return to normal reference levels.
cRp, the first App to be discovered, has a molecular weight of 
100 kDa. higher mortalities have been associated with elevations in 
plasma concentrations of cRp in cases of aortic aneurysm in human 
beings (schillinger and others 2002). cRp has also been shown to 
be a sensitive and inexpensive marker of inflammation for the early 
diagnosis of bacterial infection after orthopaedic surgery in human 
beings (Waleczek and others 1991). In dogs, cRp has been shown 
to be elevated in various disorders, including pancreatitis, pyometra, 
pneumonia, immune-mediated haemolytic anaemia and postsurgical 
trauma (Yamamoto and others 1993, 1994, Fransson and others 2004, 
holm and others 2004, couto and others 2009, Mitchell and others 
2009). A decrease in the level of cRp has also been shown to be cor-
related with survival in dogs with systemic inflammatory response 
syndrome or sepsis (Gebhardt and others 2009).
sAA is a small serum protein with a molecular weight of 
11,685 Da. It is produced by hepatocytes and is a non-specific marker 
of infectious, inflammatory, immunological and traumatic disease 
(eckersall 1995). the plasma concentrations of sAA have been shown 
to increase more rapidly compared with other Apps; in dogs, horses 
and human beings the plasma concentrations may increase 100- to 
1000-fold in response to acute inflammation (pepys and others 1989, 
eckersall and others 1999a, Glojnaric and others 2001).
hp is a glycoprotein that is synthesised in the liver. Its primary role 
is in the complexing of free haemoglobin after intravascular haemo-
lysis. serum concentrations of hp decrease in cases of haemolytic dis-
ease and increase in response to inflammatory disease (Mischke and 
others 2007).
canine AGp, as in other species, is a protein with an unusually 
high proportion of glycosyl groups (45 per cent) contributing to its 
molecular weight of 43 kDa. changes in glycosylation of AGp have 
been described in human beings and also in cats with feline infectious 
peritonitis (ceciliani and others 2004).
canine nasal disease is a common clinical entity seen in small 
animal practice, which can arise due to neoplasia, foreign bodies, 
 inflammation, bacterial, mycotic or parasitic infections and dental dis-
ease (tasker and others 1999, Meler and others 2008). the aetiology 
of nasal disease in dogs remains a diagnostic challenge, and a definitive 
diagnosis cannot be made from clinical findings alone. Diagnosis of 
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canine nasal disease usually requires a combination of investigative 
techniques including radiography, ct, MRI, rhinoscopy, bacteriol-
ogy, mycology and cytological or histological examination of nasal 
samples collected at the time of investigation. A recent retrospective 
study showed that a definitive diagnosis could not be established in 
36.3 per cent of cases of canine nasal disease (Meler and others 2008).
the purpose of this study was to determine whether serum con-
centrations of Apps alter in clinical cases of canine nasal disease, and 
to investigate whether there is a significant variation in plasma App 
concentrations among the different phenotypic groups diagnosed.
Materials and methods
client-owned dogs presented to the authors’ institutions between 
september 2007 and september 2009 with a history of persistent 
nasal disease were considered eligible for inclusion in the study. All the 
cases received a full clinical examination with specific emphasis on 
nasal examination. this included examination of the external nares 
for evidence of discharge and the nature of the discharge, if any; exam-
ining for evidence of nasal planum ulceration or depigmentation; vis-
ual examination and palpation for the presence of facial asymmetry 
and/or pain; assessment of nasal patency; and palpation of regional 
lymph nodes for evidence of enlargement.
Blood samples were collected at the time of presentation and 
before any invasive procedures, for routine haematology, biochem-
istry and aspergillosis serology tests and an App panel. the panel 
of Apps run for this study was measured on residual samples taken 
for a primary clinical purpose, which would have otherwise been 
discarded as clinical waste. the panel comprised cRp, sAA, AGpt 
and hp. serum samples taken for analysis of the Apps were stored 
at −20°c until assayed. the concentrations of the Apps were deter-
mined as described previously by Lowrie and others (2009a, b). the 
cRp immunoturbidimetric assay and hp haemoglobin binding 
capacity assays have been described earlier by eckersall and others 
(1991, 1999b). sAA was measured using a commercial canine eLIsA 
kit (tridelta Development), and AGp was measured using a com-
mercial radial immunodiffusion assay (J-path) in accordance with 
the manufacturer’s instructions. the limit of detection of the cRp 
immunoassay, based on 2 sd from blank samples with zero or negli-
gible amounts of cRp, was 0.78 mg/l, and had interassay coefficients 
of variation (cVs) (n=20) of 24 and 24 per cent with control samples 
of 39 and 140 mg/l, respectively. For sAA, the limit of detection was 
0.12 mg/l with interassay cVs (n=9) of 31 and 12 per cent with 
control samples of 9.3 and 50 mg/l, respectively. Although these cVs 
were higher than for clinical chemistry analytes, they were consid-
ered acceptable for immunoassay because they were all less than the 
recommended 25 per cent (Findlay and others 2000) except for sAA 
at a low concentration (9.3 mg/l, cV=31 per cent). however, given 
that the serum concentration of this analyte in dogs can rise to over 
2000 mg/l (Lowrie and others 2009b) and given the large dynamic 
range, this higher cV was also considered acceptable. the limit of 
detection of the hp assay was 0.02 g/l and interassay cVs (n=18) 
were 5 and 7 per cent with control samples of 0.3 and 1.0 g/l, respec-
tively. the limit of detection of the AGp assay was 0.02 g/l and a 
control sample concentration of 0.43 g/l (n=3) had an interassay cV 
of 2.7 per cent.
the serum App concentration results from the dogs with nasal 
disease were compared with those from dogs (irrespective of breed, age 
or sex) that were free from inflammatory or infectious disease. serum 
samples previously described by Mischke 
and others (2007) were included in the 
control samples for this study. however, 
not all samples from healthy dogs from the 
laboratory’s serum bank were available for 
all App assays. the sera were assayed for 
concentrations of cRp (n=51), hp (n=54), 
AGp (n=37) and sAA (n=39), using the 
methods described above.
Diagnostic imaging procedures were 
performed for all dogs under sedation or 
general anaesthesia. these included radi-
ography of the nasal cavities (right or left 
lateral, intraoral dorsoventral and rostro caudal view of frontal sinus), 
ct or MRI.
the nasopharynx and choanae of all the dogs were examined 
with a retroflexed endoscope using an 8.5 mm flexible videoendo-
scope (Olympus) for evidence of loss of symmetry, inflammation, 
foreign bodies or masses. the pharynx was packed with gauze swabs 
and a 30° 9.5 Fr (including sheath) rigid cystoscope (Karl storz) with 
a sterile saline flushing channel was used for anterograde rhinoscopy. 
the dorsal and ventral meatus were inspected for evidence of neopla-
sia, fungal plaques, turbinate destruction and foreign bodies. Biopsy 
samples collected during endoscopic examination were submitted for 
histopathological examination and bacterial and fungal culture.
the dogs were assigned to one of three groups – neoplasia, 
aspergillosis or chronic rhinitis – based on the diagnostic imaging find-
ings, positive results for either fungal culture or aspergillosis serology 
and the results of the histological analysis.
the data were explored graphically and statistical comparisons 
of App levels among groups (control, aspergillosis, rhinitis and neo-
plasia) were carried out using Kruskal-Wallis tests. Mann-Whitney 
u tests were used for post hoc pairwise comparisons. significance 
was set at p<0.05, and multiple comparisons were accounted for 
using a Bonferroni correction. All analyses were undertaken in R 
(R Development core team 2009).
Dogs were excluded from the study if they had received ster-
oid treatment in the seven days before App sampling, because ster-
oid treatment is known to stimulate the production of hp in dogs 
(Martínez-subiela and others 2004, cerón and others 2005).
this study was approved by the welfare and ethics committee of 
the university of Glasgow.
Results
Forty-eight dogs with nasal disease were included in the study. the 
animals were assigned to one of three groups depending on their diag-
nosis: neoplasia (n=18), aspergillosis (n=13) and rhinitis (n=17). the 
mean (sd) age of the animals in the study was 7.79 (2.82) years (range 
0.5 to 12 years). the breeds included cocker spaniel (n=5), golden 
retriever (n=5), Border collie (n=3), staffordshire bull terrier (n=3), 
German shepherd dog (n=3), rottweiler (n=3), West highland white 
terrier (n=2), Jack Russell terrier (n=2), springer spaniel (n=2), lurcher 
(n=2), cavalier King charles spaniel (n=2), samoyed (n=2) and one 
each of the following: German pointer, bull mastiff, boxer, labrador 
retriever, briard, english bulldog, greyhound and German visla. there 
were also six crossbreed dogs.
the median and range of cRp concentrations in the three groups 
of dogs with nasal disease are given in table 1 and shown in Fig 1, 
along with the concentrations found in healthy dogs (Mishke and oth-
ers 2007). post hoc comparisons revealed that serum samples from 
each of the three groups of dogs with nasal disease had elevated cRp 
concentrations compared with the samples from healthy animals 
(p<0.001 for each group relative to controls). however, there were no 
significant differences in cRp levels among the groups with different 
nasal diseases.
the median and range of hp concentrations in the three groups of 
dogs with nasal disease are given in table 1 and shown in Fig 2, along 
with the concentrations found in healthy dogs. Again, post hoc com-
parisons identified the differences between the serum samples from 
each of the diseased groups and the samples from healthy animals 
to be statistically significant (p<0.001 for each group relative to con-
TABLE 1: Median and range of serum acute phase protein concentrations in groups of dogs 
with nasal disease and healthy dogs
C-reactive protein (mg/l) Haptoglobin (g/l ) α
1
-acid glycoprotein (g/l ) Serum amyloid A (mg/l )
Disease group Median (n) Range Median (n) Range Median (n) Range Median (n) Range
Aspergillosis 13.4** (13)  2-82 5.2**† (13) 2.0-19.2 0.38 (10) 0.23-0.88 0.63 (10) <0.12-64
Rhinitis  4.8** (17)  1-44 2.9** (17) 0.8-5.8 0.42 (16) 0.17-2.4 0.41 (16) 0.13-5.5
Neoplasia 14.8** (18) <0.78-69 4.1** (18) 0.30-10.8 0.42 (18) 0.27-3.7 0.82* (18) 0.22-35.7
Healthy dogs 1.5 (51) <0.78-9.6 0.65 (54) <0.02-4.3 0.42 (37) 0.24-0.77 0.49 (39) <0.12-8.8
* Significantly different from the healthy group (P<0.05), ** Significantly different from the healthy group (P<0.001)
† Significantly different from the rhinitis group P<0.01
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trols). the median hp concentration in the aspergillosis group (5.2 g/l) 
was also found to be significantly different (p<0.01) from the median 
concentration in the rhinitis group (2.9 g/l).
the median and range of AGp concentrations in the three groups 
of dogs with nasal disease are given in table 1 and shown in Fig 3, 
along with the concentrations found in healthy dogs. there were no 
significant differences among the groups (p=0.612) as determined by 
non-parametric analysis of variance (Kruskal-Wallis test), irrespective 
of whether the samples from the healthy group were included in the 
analysis.
the median and range of sAA concentrations in the three groups 
of dogs with nasal disease are given in table 1 and shown in Fig 4, 
along with the concentrations found in healthy dogs. A significant 
difference (p<0.05) was found between the neoplasia group and the 
control group.
Discussion
Apps are widely used as non-specific markers of inflammation in 
dogs (eckersall 2000, cerón and others 2005). Recent publications 
have shown that Apps aid in the diagnosis of certain conditions and 
are of prognostic value (conner and others 1988, holm and others 
2004, Gebhardt and others 2009). Apps have also been shown to be 
elevated in normal physiological conditions such as pregnancy (ulutas 
and others 2009). Recent studies in children have shown that cRp is 
downregulated in allergic rhinitis (steiner and others 2006).
canine sAA and cRp have been shown to be the major Apps in 
dogs (cerón and others 2005). changes in cRp and sAA have been 
shown to occur in pathological conditions such as sepsis (Gebhardt 
and others 2009), steroid-responsive meningitis-arteritis (sRMA) 
(Lowrie and others 2009a), and in bitches with pyometra being moni-
tored for postoperative complications (Dabrowski and others 2009).
In the present study, cRp levels were found to be significantly 
higher in dogs with nasal disease (irrespective of the type of nasal 
disease) compared with controls (p<0.001). this was an expected 
finding, on the basis of results from earlier studies evaluating cRp 
in dogs with other inflammatory, infectious and neoplastic diseases 
(Burton and others 1994, Mischke and others 2007, planellas and 
others 2009). the results of the sAA analysis show a significant dif-
ference between the neoplasia group (p<0.05) and the control group 
(p<0.05), but not between the aspergillosis group or chronic rhinitis 
group and the control group. the explanation for the significantly 
higher relative levels of cRp but not of sAA in the aspergillosis and 
rhinitis groups compared with the controls is not clear. the findings 
suggest, however, that the mechanisms that control these major Apps 
in dogs are different from those in human beings (cerón and others 
2005). It is possible that sAA production is stimulated only under 
certain conditions or at particular levels of pathogenesis. the results 
of the present study contrast with those of a study that investigated 
the App response to sRMA (Lowrie and others 2009a). It is evident 
that sRMA caused the stimulation of both Apps, possibly due to dif-
ferences in the locations of the lesions or to the severity of the inflam-
matory process. Further investigation is warranted to determine the 
explanation for this finding, and to interpret the differential elevations 
FIG 1: Serum concentrations of C-reactive protein in dogs 
with aspergillosis (n=13), rhinitis (n=17) and neoplasia (n=18) 
compared with those of healthy dogs (n=51)
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FIG 2: Serum concentrations of haptoglobin in dogs with 
aspergillosis (n=13), rhinitis (n=17) and neoplasia (n=18) 
compared with those of healthy dogs (n=54)
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FIG 3: Serum concentrations of α1-acid glycoprotein in dogs 
with aspergillosis (n=10), rhinitis (n=16) and neoplasia (n=18) 
compared with those in healthy dogs (n=37)
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FIG 4: Serum concentrations of serum amyloid A in dogs with 
aspergillosis (n=10), rhinitis (n=16) and neoplasia (n=18) 
compared with those in healthy dogs (n=39)
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of these Apps under different conditions with a view to improving the 
accuracy of diagnosis.
hp and AGp are Apps that show moderate elevation in levels 
during acute phase reactions (cerón and others 2005). the con-
centrations of hp and AGp have been shown to increase in many 
infectious and inflammatory conditions, including surgical trauma 
(conner and others 1988), sRMA (Lowrie and others 2009a) and 
lymphatic neoplasia (Mischke and others 2007). significant dif-
ferences in hp concentrations (p<0.001) were found between the 
groups of animals with nasal disease and the control group, but no 
differences were found in the mean AGp concentrations among the 
groups. In addition, a significant difference (p<0.01) was detected 
between the serum concentrations of hp in the aspergillosis group 
and the chronic rhinitis group. Of the moderate Apps in dogs, hp 
has been found to be more responsive than AGp in other conditions 
such as sRMA. A significant increase in serum hp concentration 
has also been shown after administration of different dosages of 
exogenous glucocorticoids (cerón and others 2005). the samples 
for the present study were taken at least seven days after any ster-
oid treatment and therefore the significant increases in hp concen-
tration found here were not likely to be due to an iatrogenic effect 
(Martínez-subiela and others 2004). A more valid explanation would 
be that hp shows a greater response to the on-going nature of the 
inflammatory response in these diseases than AGp does. Recently, 
the role of Apps in monitoring disease progression has been shown 
to have some validity (Gebhardt and others 2009, Lowrie and others 
2009b). 
canine aspergillosis is a common clinical entity. effective con-
trol of the disease has often been difficult to achieve, and a wide 
variety of treatment modalities has been investigated, including 
topical and systemic administration of antifungal agents or com-
binations of the two routes of administration (sissener and others 
2006, peeters and clercx 2007). Affected dogs are often left with 
a chronic nasal discharge due to turbinate destruction, which can 
make the decision to terminate treatment difficult. the significant 
difference in the expression of hp in dogs with aspergillosis and 
those with chronic rhinitis provides a basis to examine cases after 
treatment in order to determine whether resolution of the App rise 
is confined only to cases in which the outcome of treatment is a suc-
cess. this knowledge may be useful in the therapeutic management 
of aspergillosis cases and in differentiating active aspergillosis from 
chronic rhinitis.
A number of outliers were identified. A 12-year-old dog that was 
diagnosed with nasal aspergillosis had a depressed skull fracture and 
an organising haematoma. Another outlier was an 11-year-old rott-
weiller with a nasal sarcoma and severe osteoarthritis. this finding is 
interesting, given that marked elevations in one or more of the App 
markers may prompt the clinician to look for concurrent or underly-
ing pathology that may be of clinical significance when treating cases 
of nasal disease.
the limitations of this study include the small number of cases in 
the individual groups and the retrospective nature of the analysis. the 
median value of cRp was elevated in both the neoplasia (14.8 mg/l) 
and aspergillosis (13.4 mg/l) groups compared with the chronic rhini-
tis (4.8 mg/l) group, although no significant inter-group difference 
was found. Future studies with larger numbers of cases in each group 
may show significant inter-group differences. this study has shown 
that cRp and hp are useful biomarkers to detect nasal inflammation. 
Whether the concentrations of Apps in dogs with rhinitis can be used 
as prognostic factors or to monitor the development of the disease has 
to be investigated in further studies.
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